B. Riley Securities Maintains Buy on Perspective Therapeutics, Raises Price Target to $1.7
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Yuan Zhi has maintained a Buy rating on Perspective Therapeutics (AMEX:CATX) and increased the price target from $1.2 to $1.7.
April 09, 2024 | 5:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B. Riley Securities has maintained a Buy rating on Perspective Therapeutics and raised the price target from $1.2 to $1.7.
The upgrade in price target by a reputable analyst like Yuan Zhi from B. Riley Securities typically signals a strong bullish sentiment on the stock, suggesting a positive short-term price movement. The increase from $1.2 to $1.7 represents a significant upward revision, indicating improved fundamentals or future prospects for Perspective Therapeutics.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100